ReShape Lifesciences — EnteroMedics — Canaccord Genuity Presentation (August 2011)
25 slides from ReShape Lifesciences's conference presentation, Aug 11, 2011
Slide 1: Canaccord Genuity Presentation
Exhibit 99.1 Canaccord Genuity Presentation August 11, 2011
Slide 2: Safe Harbor Statement
Safe Harbor Statement Thispresentationcontainsforward-lookingstatementsabout EnteroMedicsInc. Our actual results could differ materiallyfrom those discusseddue to known and unknown risks,uncertaintiesand other factors includingour limited history of operations;our lossessinceinceptionand for the for
Slide 3: EnteroMedics: Leader in neuroblocking with strong IP
EnteroMedics Leader in neuroblocking with strong IP Data in >400 patients support VBLOC therapy as safe and effective in obesity. Promising results in type 2 diabetes – Clinically significant weight loss – Improvement in glycemic control – Reduction in blood pressure in hypertensive patients – Excel
Slide 4: The Obesity Epidemic in the US
The Obesity Epidemic in the US 1/3 of US adults are obese – More than 72 million people in the US (Body Mass Index “BMI” >30) – 1 in 8 deaths in the US are caused by an overweight/obesity related illness – CDC estimates an overall economic cost of obesity of approximately $150 billion Approximately
Slide 5: Current Treatments
Current Treatments Pharmaceuticals Bariatric Surgery Less Invasive More Invasive Serious safety concerns, esp. cardiac Bypass & sleeve surgery irreversible and risky Adverse side-effects All result in long-term complications and major lifestyle changes, e.g., dietary restrictions and nutritional Les
Slide 6: Role of the Vagus Nerve
Role of the Vagus Nerve Vagus nerve controls: – Sensation of hunger 20% of vagus – Expansion, fullness and emptying nerve fibers send of stomach instructions from the brain – Digestive enzyme secretion Severing the vagus nerve (vagotomy) causes: 80% of vagus nerve fibers – Reduced appetite send mess
Slide 7: VBLOC Therapy
VBLOC Therapy Delivered via the Maestro System VBLOC Therapy – First in class n –on-punitive; direct effect on mechanism of metabolic disease – Intermittent neuroblockingtechnology blocks vagus nerve signals, therefore reducing hunger feelings and promoting earlier fullness – Subcutaneously implante
Slide 8: Compelling Proof of Concept
Compelling Proof of Concept Significant impact on hunger and fullness drives successful weight loss Earlier Fullness and Less Hunger Reduced Portion Size Reduced Calories 90% 2250 30% Earlier Protein Carbohydrates Fat % EWL from 25% fullness 2000 Implant 20% 60% 1750 20% 15% 10% 30% 1500 5% 0% 1250
Slide 9: The Maestro System
The Maestro System Clinical Experience Safety Efficacy No therapy related SAEs; Low overall SAE rate Clinically significant weight-loss Positive safety profile, including CV Control of major co-morbidities – Diabetes and hypertension Study Location # Patients Study Efficacy ~400 Overall Duration (yr
Slide 10: Pivotal Trials
Pivotal Trials EMPOWER – 294 subjects Double blind, placebo controlled randomized trial BMI range 35 to 39.9 with co-morbidity; 40 to 45 with or without – Endpoints Primary efficacy: Greater efficacy in treated arm versus control arm Secondary efficacy: Greater proportion of treated subjects versus
Slide 11: Maestro System: Usage equals Results
Maestro System Usage equals RESULTS EMPOWER Trial Outcome Mean Excess Weight Loss (EWL) by Hours of Use in Treatment Group 0 “Dose Effect”shows clear < 6hr correlation between -5 (n = 25) average EWL and the -10 number of hours of device 6 - 9hr (n = 61) use -15 – Demonstrates efficacy -20 9 - 12hr
Slide 12: EMPOWER Trial Summary
EMPOWER Trial Summary Both groups experienced significant, dose-dependent Excess Weight Loss (EWL) – EWL greater than 20% in the prescribed use group of both arms – An unanticipated therapeutic effect was seen in the placebo arm Safety endpoint met – No deaths, low 1-yr surgical revision rate and lo
Slide 13: US RECHARGE Trial
US RECHARGE Trial Pivotal Trial for US Approval Use next generation implantable device – More convenient – Hours of use controlled by device Placebo group receives non-active device – No charge delivered Approximately 234 morbidly obese subjects – 2:1 randomization – Treated group “on”for ~12 hrs pe
Slide 14: VBLOC-DM2 ENABLE Trial
VBLOC –DM2 ENABLE Trial Diabetes and Hypertension Design:prospective, open-label, multi-center, 12 month trial Cohort:28 patients with obesity and type 2 diabetes, 18 with hypertension Inclusion criteria: – BMI 30 to 40 kg/m2 – NIDDM, <12 yrs duration – HbA1c levels >7% to <10% – Absence of signific
Slide 15: VBLOC-DM2 ENABLE Trial: %EWL Results
VBLOC –DM2 ENABLE Trial %EWL Results 0 -5 -10 - 15 - 20 - 25 n=26 -30 n=24 n=22 n=24 - 35 Implant 3 Months 6 Months 12 Months 18 Months *N represents subjects using the device for 12 hours or more 15
Slide 16: Change in Fasting Glucose
Change in Fasting Glucose Week 1 Week 4 Week 12 6 Months 12 Months 18 Months 0 -10 -20 * * -30 n=28 n=27 * n=26 * -40 n=25 * n=25 -50 At all time points, changes are significant with p<0.01 * Baseline= 151.4± 6.5 mg/dl n=12 -60
Slide 17: Change in HbA1c %
Change in HbA1c % Week 1 Week 4 Week 12 6 Months 12 Months 18 Months 17
Slide 18: Change in Diastolic Blood Pressure in Patients with Elevated DBP
Change in Diastolic Blood Pressure in Patients with Elevated DBP Week 1 Wk 1 Week 4 Wk 4 6 Months 6 Mo 12 12 Months Mo 1818Months Mo 0 -5 n= 12 n= 12 n= 11 -10 n= 10 -15 n= 10 -20 At all time points statistically significant with p<.01 Baseline= 87.5± 2.2 mmHg
Slide 19: Change in Mean Arterial Pressure in Patients with Hypertension
Change in Mean Arterial Pressure in Patients with Hypertension Week 1 Week 12 6 Months 12 Months 18 Months 0 -5 n= 15 n= 14 n= 14 -10 n= 13 n= 13 -15 At all time points statistically significant with p=.04 Baseline= 100.1± 2.4mmHg -20
Slide 20: No Change in Blood Pressure in Normotensive Patients
No Change in Blood Pressure in Normotensive Patients Week 1 Week 4 Week 12 6 Months 12 Months 10 3.2 8 n=4 6 0.5 4 n=10 2 0 -2 -4 -1.0 -1.8 -6 n=10 n=10 -8 -3.2 Baseline MAP = 89.0 ±1.1 mmHg n=10 -10 Week 1 Week 4 Week 12 6 Months 12 Months
Slide 21: Significant Promise in Treatment of Metabolic Disease
Significant Promise in Treatment of Metabolic Disease Diabetes and Hypertension Clinically significant effect of VBLOC on two major co-morbidities – Type 2 Diabetes Mellitus • About 26 million people in US and more than 220 million people worldwide have diabetes – Cardiovascular / blood pressure • A
Slide 22: Commercialization in Europe and Australia
Commercialization in Europe and Australia Australia – Historical leadership with new obesity treatments – Extensive clinical experience with the Maestro System • Australian Institute of Weight Control (AIWC) – Device Technologies Australia • Distributor • Regulatory and reimbursement support – TGA a
Slide 23: Financial Summary
Financial Summary Balance Sheet Data NASDAQ: ETRM As of June 30, 2011 Diluted Shares Outstanding Cash and cash equivalents $27.4 million As of June 30, 2011 Total invested capital CommonShares $171 million 27.9 million Warrants 22.2 million Options 2.0 million DilutedSharesOutstanding 52.1million 23
Slide 24: EnteroMedics: Leader in neuroblocking with strong IP
EnteroMedics Leader in neuroblocking with strong IP Data in >400 patients support VBLOC therapy as safe and effective in obesity. Promising results in type 2 diabetes – Clinically significant weight loss – Improvement in glycemic control – Reduction in blood pressure in hypertensive patients – Excel
Slide 25: Slide 25
EnteroMedics — Canaccord Genuity Presentation (August 2011) on 6ix